Quality of Life Evaluation in Patients with Follicular Cell Lymphoma: A Real-World Study in Europe and the United States

• Published in: Advances in therapy 2024-08, Vol.41 (8), p.3342-3361
• Main Authors: Johnson, Patrick Connor, Bailey, Abigail, Ma, Qiufei, Milloy, Neil, Biondi, Emilia, Quek, Ruben G. W., Weatherby, Sarah, Barlow, Sophie
• Format: Article
• Language: English
• Subjects: Aged; Cardiology; Cross-Sectional Studies; Endocrinology; Europe; Female; Humans; Internal Medicine; Lymphoma, Follicular - psychology; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Research; Patient Reported Outcome Measures; Pharmacology/Toxicology; Quality of Life; Rheumatology; United States
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-024-02882-1

Introduction Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL), characterized by a long natural course of remissions/relapses. We aimed to evaluate real-world quality of life (QoL) in patients with FL, by line of therapy (LOT), and across countries. Methods Data were drawn from the Adelphi FL Disease Specific Programme™, a cross-sectional survey of physicians and their patients in Europe [France, Germany, Italy, Spain, the United Kingdom (UK)], and the United States (US) from June 2021 to January 2022. Patients provided demographics and patient-reported outcomes via the European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30). Bivariate analysis assessed QoL versus NHL, across LOT [first line (1L), second line (2L), third line or later (3L+)] and country. Results Patients ( n  = 401) had a mean [standard deviation (SD)] age of 66.0 (9.24) years, 58.1% were male, and 41.9%/22.9% were Ann Arbor stage III/IV. Patients with FL mean EORTC global health status (GHS)/QoL, nausea/vomiting, pain, dyspnea, appetite loss, and diarrhea scores were statistically significantly worse ( p